Literature DB >> 16584287

Placental transfer of ondansetron during early human pregnancy.

Shing-Shun N Siu1, Matthew T V Chan, Tze-Kin Lau.   

Abstract

BACKGROUND AND
OBJECTIVE: Nausea and vomiting are common conditions that occur during early pregnancy and can be disabling. Ondansetron had been used in pregnant women when treatment with conventional antiemetics has failed; however, the safety and tolerability of this relatively new antiemetic drug during pregnancy is still uncertain. The objective of this study was to quantify the placental transfer of ondansetron in the first trimester of human pregnancy. PATIENTS AND METHODS: This was a prospective, observational study. Forty-one patients who requested surgical termination of pregnancy at the first trimester were administered three doses of ondansetron 8 mg before surgery. Maternal venous blood, coelomic fluid, amniotic fluid and fetal tissue were collected from each patient for analysis of ondansetron by liquid chromatography-mass spectometry.
RESULTS: Ondansetron was found in all samples. Drug concentration in fetal tissue was significantly higher than that in the amniotic fluid and similar to that in the coelomic fluid. The median (interquartile range) fetal/maternal ratio was 0.41 (0.31-0.52) and there were no significant correlations between ondansetron concentrations in each compartment and gestational age.
CONCLUSIONS: A significant amount of ondansetron was present in all embryonic compartments. The developmental significance of this drug exposure requires further investigation, i.e. whole embryo culture.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584287     DOI: 10.2165/00003088-200645040-00006

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  20 in total

Review 1.  Fluid compartments of the embryonic environment.

Authors:  E Jauniaux; B Gulbis
Journal:  Hum Reprod Update       Date:  2000 May-Jun       Impact factor: 15.610

2.  Ondansetron and hyperemesis gravidarum.

Authors:  E Guikontes; A Spantideas; J Diakakis
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

3.  The determination in plasma and pharmacokinetics of ondansetron.

Authors:  P V Colthup; J L Palmer
Journal:  Eur J Cancer Clin Oncol       Date:  1989

4.  A study on placental transfer of diclofenac in first trimester of human pregnancy.

Authors:  S S Siu; J H Yeung; T K Lau
Journal:  Hum Reprod       Date:  2000-11       Impact factor: 6.918

5.  A pilot study of intravenous ondansetron for hyperemesis gravidarum.

Authors:  C A Sullivan; C A Johnson; H Roach; R W Martin; D K Stewart; J C Morrison
Journal:  Am J Obstet Gynecol       Date:  1996-05       Impact factor: 8.661

6.  Ondansetron: pre-clinical safety evaluation.

Authors:  M L Tucker; M R Jackson; M D Scales; N W Spurling; D J Tweats; K Capel-Edwards
Journal:  Eur J Cancer Clin Oncol       Date:  1989

Review 7.  Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP).

Authors:  Laura A Magee; Paolo Mazzotta; Gideon Koren
Journal:  Am J Obstet Gynecol       Date:  2002-05       Impact factor: 8.661

8.  An in-vivo study on placental transfer of naproxen in early human pregnancy.

Authors:  S S N Siu; J H K Yeung; T K Lau
Journal:  Hum Reprod       Date:  2002-04       Impact factor: 6.918

9.  Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century.

Authors:  G J Annas; S Elias
Journal:  Am J Public Health       Date:  1999-01       Impact factor: 9.308

10.  The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study.

Authors:  Adrienne Einarson; Caroline Maltepe; Yvette Navioz; Deborah Kennedy; Michael Paul Tan; Gideon Koren
Journal:  BJOG       Date:  2004-09       Impact factor: 6.531

View more
  5 in total

1.  PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.

Authors:  Rachel Huddart; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-06       Impact factor: 2.089

2.  Integrative exposomic, transcriptomic, epigenomic analyses of human placental samples links understudied chemicals to preeclampsia.

Authors:  Alex Chao; Jarod Grossman; Celeste Carberry; Yunjia Lai; Antony J Williams; Jeffrey M Minucci; S Thomas Purucker; John Szilagyi; Kun Lu; Kim Boggess; Rebecca C Fry; Jon R Sobus; Julia E Rager
Journal:  Environ Int       Date:  2022-06-30       Impact factor: 13.352

3.  Ondansetron use in the first trimester of pregnancy and the risk of neonatal ventricular septal defect.

Authors:  Lara S Lemon; Lisa M Bodnar; William Garrard; Raman Venkataramanan; Robert W Platt; Oscar C Marroquin; Steve N Caritis
Journal:  Int J Epidemiol       Date:  2020-04-01       Impact factor: 7.196

4.  Off-label use of ondansetron in pregnancy in Western Australia.

Authors:  Lyn Colvin; Andrew W Gill; Linda Slack-Smith; Fiona J Stanley; Carol Bower
Journal:  Biomed Res Int       Date:  2013-12-12       Impact factor: 3.411

5.  Minimal effective weight-based dosing of ondansetron to reduce hypotension in cesarean section under spinal anesthesia: a randomized controlled superiority trial.

Authors:  Maliwan Oofuvong; Thitikan Kunapaisal; Orarat Karnjanawanichkul; Nussara Dilokrattanaphijit; Jaranya Leeratiwong
Journal:  BMC Anesthesiol       Date:  2018-08-15       Impact factor: 2.217

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.